| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats
|
Li, Xin-mei
|
|
|
90 |
6 |
p. 499-510
|
article
|
| 2 |
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
|
Kitano, Shigehisa
|
|
|
90 |
6 |
p. 523-529
|
article
|
| 3 |
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16
|
Ma, Liya
|
|
|
90 |
6 |
p. 431-444
|
article
|
| 4 |
A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL)
|
Johnson, Suja
|
|
|
90 |
6 |
p. 445-453
|
article
|
| 5 |
Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study
|
Kotani, Naoki
|
|
|
90 |
6 |
p. 511-521
|
article
|
| 6 |
Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways
|
Lin, Hai
|
|
|
90 |
6 |
p. 455-465
|
article
|
| 7 |
Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab
|
Sharaf, Basma M.
|
|
|
90 |
6 |
p. 467-488
|
article
|
| 8 |
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia
|
Jian, Weizhe
|
|
|
90 |
6 |
p. 489-497
|
article
|
Journal description